Loading clinical trials...
Loading clinical trials...
A Phase III Study to Evaluate the Efficacy of INM004 (Shiga Antitoxin) in Pediatric Patients With Shiga Toxin-producing Escherichia Coli-associated Hemolytic Uremic Syndrome.
Conditions
Interventions
INM004
Placebo
Locations
52
Argentina
Hospital Interzonal Dr. José Penna
Bahía Blanca, Buenos Aires, Argentina
Hospital Penna
Bahía Blanca, Buenos Aires, Argentina
Hospital de niños Sor María Ludovica
La Plata, Buenos Aires, Argentina
Clinica del niño y la madre
Mar del Plata, Buenos Aires, Argentina
Hospital Interzonal Especializado Materno Infantil Don Victorio Tetamanti
Mar del Plata, Buenos Aires, Argentina
Sanatorio de la Trinidad Ramos Mejia
Ramos Mejía, Buenos Aires, Argentina
Start Date
October 5, 2024
Primary Completion Date
August 30, 2026
Completion Date
December 31, 2026
Last Updated
January 15, 2026
NCT05219110
NCT01194973
NCT01193348
NCT01666548
NCT01406288
Lead Sponsor
Inmunova S.A.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions